GIBSON DUNN

# Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen’s Imdelltra

Firm News | August 26, 2025

---

Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to $950 million.

Royalty Pharma will pay $885 million upfront, and BeOne retains the option to sell an additional portion of its royalty to Royalty Pharma for up to $65 million within the next 12 months, in exchange for an approximately 7% royalty on worldwide net sales of Imdelltra.

Our corporate team includes partners Karen Spindler, Ryan Murr, and associate Ayushi Sutaria.

### Related People

Karen A. Spindler

Ryan A. Murr

Ayushi Sutaria

### Related Capabilities

Mergers and Acquisitions

Life Sciences

Public Companies

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at <a href="https://www.gibsondunn.com">www.gibsondunn.com</a>. | **www.gibsondunn.com**